These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30793795)

  • 1. Correlation-adjusted regression survival scores for high-dimensional variable selection.
    Welchowski T; Zuber V; Schmid M
    Stat Med; 2019 Jun; 38(13):2413-2427. PubMed ID: 30793795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.
    Ternès N; Rotolo F; Michiels S
    BMC Med Res Methodol; 2017 May; 17(1):83. PubMed ID: 28532387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
    Kim D; Li R; Dudek SM; Ritchie MD
    J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair-Related Genes.
    Zhang D; Yang S; Li Y; Yao J; Ruan J; Zheng Y; Deng Y; Li N; Wei B; Wu Y; Zhai Z; Lyu J; Dai Z
    JAMA Netw Open; 2020 Oct; 3(10):e2014622. PubMed ID: 33017027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting the discriminatory power of sparse survival models via optimization of the concordance index and stability selection.
    Mayr A; Hofner B; Schmid M
    BMC Bioinformatics; 2016 Jul; 17():288. PubMed ID: 27444890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
    Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
    Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
    [No Abstract]   [Full Text] [Related]  

  • 10. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
    Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
    PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
    Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
    Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
    Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
    Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
    Liu B; Li X; Li J; Jin H; Jia H; Ge X
    Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On evaluating how well a biomarker can predict treatment response with survival data.
    Mboup B; Blanche P; Latouche A
    Pharm Stat; 2020 Jul; 19(4):410-423. PubMed ID: 31943737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
    Schmidtmann I; Elsäßer A; Weinmann A; Binder H
    Stat Med; 2014 Dec; 33(30):5358-70. PubMed ID: 25345575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Risk Prediction in Clinical Oncology Research: Applications and Practical Issues Using Survival Trees and Random Forests.
    Hu C; Steingrimsson JA
    J Biopharm Stat; 2018; 28(2):333-349. PubMed ID: 29048993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
    Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1 penalized estimation in the Cox proportional hazards model.
    Goeman JJ
    Biom J; 2010 Feb; 52(1):70-84. PubMed ID: 19937997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.